The FDA's action on Seldane leaves you in an awkward position
February 1997
The FDA's action on Seldane leaves you in an awkward position.
There have been hundreds of reports of arrhythmias and sudden death associated with Seldane (terfenadine). The FDA says it's no longer worth the risk...now that Allegra is on the market.
Allegra (fexofenadine) is the active metabolite of Seldane...it's just as effective, but without the cardiac risk.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote